Title |
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL
|
---|---|
Published in |
Clinical Pharmacokinetics, October 2016
|
DOI | 10.1007/s40262-016-0464-6 |
Pubmed ID | |
Authors |
Jennifer N. Clements, Tiffaney Threatt, Eileen Ward, Kayce M. Shealy |
Abstract |
Concentrated insulin analogs have recently been approved and are available for clinical use in the management of diabetes mellitus. One new product is insulin glargine U-300 (Sanofi), a basal concentrated insulin of 300 U/mL. Several studies have been conducted and completed evaluating blood samples for the pharmacokinetics of insulin glargine U-300 and euglycemic clamp procedures for the pharmacodynamics. This concentrated insulin has a low within-day variability and high day-to-day reproducibility, allowing for a more constant and prolonged duration of action, compared with insulin glargine U-100 (100 U/mL). Insulin glargine U-300 is equally effective, when compared with insulin glargine U-100 for glycemic control in patients with type 1 and 2 diabetes mellitus. Insulin glargine U-300 has a similar efficacy profile to insulin glargine U-100 for glycemic control, yet with lower rates of nocturnal and severe hypoglycemia. Insulin glargine U-300 can be considered an acceptable basal insulin for patients with type 1 and 2 diabetes mellitus, and it has a potential role among patients who are naïve to insulin therapy or require titration of basal insulin. Titration of insulin glargine U-300 would result in less volume and a lower risk of hypoglycemia, compared with insulin glargine U-100. This article evaluates and summarizes the pharmacokinetics and pharmacodynamics of insulin glargine U-300, for patients with type 1 or 2 diabetes mellitus, and summarizes its application to clinical practice. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 18% |
Researcher | 5 | 15% |
Student > Bachelor | 4 | 12% |
Student > Ph. D. Student | 2 | 6% |
Student > Master | 2 | 6% |
Other | 4 | 12% |
Unknown | 11 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 29% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 12% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Nursing and Health Professions | 1 | 3% |
Computer Science | 1 | 3% |
Other | 3 | 9% |
Unknown | 12 | 35% |